A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
about
Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cellsGenomic Insights into Diffuse Intrinsic Pontine Glioma.Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia.Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity
P2860
A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
@ast
A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
@en
type
label
A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
@ast
A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
@en
prefLabel
A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
@ast
A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
@en
P2093
P2860
P356
P1476
A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
@en
P2093
David C Lyden
Ira J Dunkel
Ivan Spasojevic
Jason T Huse
Jill M Kolesar
Kim Kramer
Leonard H Wexler
Oren J Becher
Sofia Haque
Stephen W Gilheeney
P2860
P356
10.1002/PBC.26409
P577
2016-12-30T00:00:00Z